The tissue is the issue: personalized medicine for non-small cell lung cancer

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 16; no. 20; pp. 4909 - 4911
Main Authors Hirsch, Fred R, Wynes, Murry W, Gandara, David R, Bunn, Jr, Paul A
Format Journal Article
LanguageEnglish
Published United States 15.10.2010
Subjects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Humans
Immunohistochemistry
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Molecular Targeted Therapy - methods
Precision Medicine - methods
Online AccessGet full text

Cover

More Information
Summary:The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-10-2005